Risk factors for loco-regional recurrence in breast cancer patients: a retrospective study
Metrics: PDF 646 views | HTML 946 views | ?
Tomás Merino1,*, Teresa Ip1,*, Francisco Domínguez2, Francisco Acevedo1, Lidia Medina1, Alejandra Villaroel3, Mauricio Camus2, Eugenio Vinés1 and César Sánchez1
1Department of Hematology-Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile
2Department of Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile
3Department of Pathology, Pontificia Universidad Católica de Chile, Santiago, Chile
*These authors contributed equally to this work
Tomás Merino, email: email@example.com
Keywords: breast cancer; local recurrence; regional recurrence; predictors; subtype
Received: January 29, 2018 Accepted: June 23, 2018 Published: July 13, 2018
Background: Although fairly uncommon, loco-regional recurrence in breast cancer (BC) has major consequences for the patient. Several predictors for locoregional have been previously reported from large randomized clinical trials mainly from Europe & North America; data from other geographical areas are somewhat scarce. Here we performed a retrospective review of medical records in a single academic center in Chile, searching for predictors of breast tumor recurrence.
Results: Median patient follow up was 61 months, 5 year overall survival (OS) rate was 94.2% (95% CI 93–95.3). We found that 108 out of 2,754 (5.3%) patients had loco-regional recurrence. The 2-year loco-regional control was 98% (95% CI 97.3–98.7) and 5-year was 94% (95% CI 92.6–95.4). Univariate analysis showed a correlation between recurrence and being <50 year-old, positive surgical margins, advanced stage, subtype, and presence of LVI and omission of adjuvant radiotherapy. Only the absence of adjuvant RT was predictor of locoregional recurrence in multivariable (p < 0.001).
Conclusions: Our study population presents high local control of BC. Age, surgical margins, stage, molecular subtype and absence of adjuvant radiotherapy were associated with loco-regional recurrence. Prospective trials and long-term follow up are required in order to confirm these results.
Materials and Methods: We analyzed medical records from 2,201 BC patients at the Pontificia Universidad Católica de Chile from 1997 to 2016. Collected data included: age at diagnosis, tumor size, axillary involvement, molecular subtype, margin status, histological grade, lympho-vascular invasion (LVI) and ipsilateral recurrence.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.